Clinical trials
Systemic Lupus Erythematosus clinical trials
Below are recruiting systemic lupus erythematosus clinical trials, each written for real people, not researchers. We’re tracking 262 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06535412RecruitingPhase 1/Phase 2
Study of IMC-002 for active lupus
This study tests a new medicine, IMC-002, for people with active lupus that hasn't been controlled by standard treatments. It aims to see if the drug can reduce lupus activity and improve symptoms.
BeijingAges 18–65 - NCT06518668Enrolling by invitationPhase 1
NKX019 cell therapy for lupus
This study tests a new therapy called NKX019, which uses specially engineered natural killer cells to target a protein on lupus cells. It is for people with moderate to severe lupus that has not responded to standard treatments, especially those with active kidney inflammation.
New York, New YorkAges 18–65 - NCT06513429Recruiting
IM19 CAR-T cell therapy for tough lupus cases
This trial tests whether a new type of immune cell therapy, called IM19 CAR-T, can help people with lupus that hasn't gotten better with standard treatments. It is designed for people ages 18 to 65 with moderate to severe disease activity.
Beijing, Beijing MunicipalityAges 18–65 - NCT07649265RecruitingPhase 1
Testing a new drug for autoimmune diseases
This study tests a new drug called HBM7020 to see if it is safe and how well it is absorbed by the body. It is for healthy people and people with certain autoimmune diseases like lupus, scleroderma, rheumatoid arthritis, or Sjögren's disease.
Brisbane, QueenslandAges 18–75 - NCT06475742Enrolling by invitationPhase 3
Long-term safety of cenerimod in lupus patients
This study tests the long-term safety of a drug called cenerimod for people with lupus (SLE) who have already completed a 12-month study of the same drug. It helps researchers see if the medicine stays safe and tolerable over a longer period.
Aurora, ColoradoAges 18–75 - NCT05714930Recruiting
Treating lupus symptoms to a clear goal
This study looks at a “treat-to-target” approach for people with systemic lupus erythematosus (SLE) to help control symptoms to a specific goal. It may help guide medication changes when lupus is not fully calm yet.
Freiburg im Breisgau, Baden-WurttembergAges 18 years+ - NCT06458075Recruiting
Improving communication and medication adherence in lupus
This study tests whether helping lupus patients and their doctors communicate better leads to taking medications more consistently. Participants will have their doctor visits recorded and use a phone app to track their medicines.
Durham, North CarolinaAges 18–90 - NCT06428188RecruitingPhase 1/Phase 2
CAR-T cells targeting BCMA/CD19 for autoimmune diseases
This trial tests a new treatment called CAR-T cells that target two proteins (BCMA and CD19) on immune cells. It is for people with certain autoimmune diseases that have not improved with standard treatments.
Beijing, Beijing MunicipalityAges 21–90 - NCT06400537RecruitingPhase 1
A-319 for active or tough-to-treat lupus (SLE)
This study tests a new drug called A-319 for people whose lupus (SLE) is active or hasn't improved with current treatments. The goal is to see if A-319 can help control lupus better.
Wuhan, HubeiAges 18–60 - NCT07657793RecruitingPhase 2/Phase 3
Sirolimus for Lupus-Related Low Platelets
This trial tests sirolimus, an immune-system-calming medicine, for people with lupus who also have very low platelet counts (ITP). It may help reduce bleeding risk and improve platelet numbers.
Beijing, Beijing MunicipalityAges 18–65 - NCT06375993Enrolling by invitationPhase 1
Prula-cel for autoimmune diseases: a phase 1 study
This trial tests a new treatment called prulacabtagene leucel (prula-cel), which is a type of immune cell therapy (CAR T-cells) for people with certain autoimmune diseases. It aims to see if it can reset the immune system and reduce disease activity in conditions like lupus, scleroderma, vasculitis, or myositis.
Redwood City, CaliforniaAges 18–80 - NCT06365359Recruiting
Lupus and pesticide exposure in Martinique
This study looks at how exposure to a pesticide called chlordecone might affect people with lupus in Martinique. Researchers want to understand if there is a link between the chemical and lupus symptoms or kidney problems.
Fort-de-FranceAges 18 years+ - NCT06340750RecruitingPhase 1
BAFF CAR-T cells for lupus that hasn't improved with standard treatments
This trial tests a new type of cell therapy called BAFF CAR-T cells (LMY-920) for lupus that hasn't gotten better with standard treatments. It aims to see if these special immune cells can help calm the overactive immune system in lupus.
Columbus, OhioAges 18–65 - NCT06347718RecruitingPhase 1/Phase 2
Car-T cells for autoimmune disease
This study tests a type of immunotherapy called CAR-T cells for people with certain autoimmune diseases like lupus, scleroderma, or myositis. It aims to see if this treatment can help when standard medicines haven't worked well enough.
Erlangen, BavariaAges 18 years+ - NCT06350110RecruitingPhase 1/Phase 2
CAR T cells for lupus
This trial tests a new type of CAR T cell therapy for people with active lupus that has not responded to other treatments. It uses specially engineered cells to target and eliminate certain immune cells that are causing the disease, with the goal of reducing symptoms and preventing flare-ups.
Beijing, Beijing MunicipalityAges 18–90 - NCT06349343RecruitingPhase 1
CAR-T cell therapy for hard-to-treat lupus
This trial tests a new type of cell therapy (CAR-T cells) that targets two proteins on immune cells (CD19 and BCMA) to treat lupus that hasn't responded to standard treatments. It may help people with moderate to severe lupus by reducing disease activity without ongoing medication.
WuhanAges 18–70 - NCT06232304Recruiting
Program for young people with childhood lupus
This study tests a program to help teenagers and young adults with childhood-onset lupus manage symptoms like fatigue, sadness, or pain. It aims to improve daily life and well-being.
Birmingham, AlabamaAges 12–22 - NCT07666711Recruiting
Kidney biomarker study for lupus patients
This study aims to find better ways to detect kidney problems in people with lupus by testing blood and urine samples. If you have lupus, you may help researchers improve how kidney disease is diagnosed and monitored.
Oslo, OsloAges 18 years+ - NCT06166199Recruiting
High-intensity interval training for lupus patients
This study tests whether high-intensity interval training (short bursts of intense exercise) can help people with systemic lupus erythematosus (SLE, an autoimmune disease). It aims to see if this type of exercise is safe and improves symptoms.
Stockholm, HuddingeAges 18 years+ - NCT06133972RecruitingPhase 3
Long-term safety of ianalumab for lupus (extension study)
This extension study tests the long-term safety of ianalumab for people with systemic lupus erythematosus. If you completed a prior SIRIUS-SLE study and your doctor thinks you'd benefit, you may continue treatment for up to 60 more weeks.
Anniston, AlabamaAges 12–100 - NCT07526350RecruitingEarly Phase 1
MTS109 for Hard-to-Treat Autoimmune Diseases
This early-stage trial tests a new treatment called MTS109 for autoimmune diseases (like lupus, muscle inflammation, scleroderma, vasculitis, or Sjögren's syndrome) that haven't responded well to standard medications. The goal is to see if MTS109 can help control disease that keeps flaring or getting worse despite current treatments.
Shanghai, Shanghai MunicipalityAges 18–65 - NCT07515638Recruiting
Immune System Study for Autoimmune Diseases
This research study collects samples and information from people with rheumatoid arthritis, lupus, or scleroderma, plus healthy volunteers, to better understand how the immune system works in these conditions. By comparing these groups, researchers hope to find new ways to treat and manage autoimmune diseases.
MontpellierAges 18 years+ - NCT06121297RecruitingPhase 1/Phase 2
CABA-201 treatment for systemic lupus erythematosus
This study tests a new treatment called CABA-201 for people with active systemic lupus erythematosus (SLE). The treatment aims to reduce disease activity and may help those who haven't responded well to other treatments.
Orange, CaliforniaAges 12–65 - NCT06106906RecruitingPhase 1/Phase 2
CD19 CAR-T for Active Lupus
This study tests a new treatment called CD19 CAR-T, which reprograms your own immune cells to attack lupus. It is for people with active lupus that has not responded well to standard therapies.
Wuhan, HubeiAges 18–70
Hear when a new Systemic Lupus Erythematosus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for systemic lupus erythematosus?
- Yes. Clin2 currently lists 262 recruiting systemic lupus erythematosus studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a systemic lupus erythematosus trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a systemic lupus erythematosus trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.